FDA Accepts NDA For Otsuka’s Novel Hyponatremia Treatment
This article was originally published in PharmAsia News
Executive Summary
FDA has accepted Otsuka's new drug application for the investigational V2-vasopressin receptor antagonist tolvaptan, which could enter an increasingly crowded market